SG11202100989UA - Novel fusion protein specific for cd137 and pd-l1 - Google Patents

Novel fusion protein specific for cd137 and pd-l1

Info

Publication number
SG11202100989UA
SG11202100989UA SG11202100989UA SG11202100989UA SG11202100989UA SG 11202100989U A SG11202100989U A SG 11202100989UA SG 11202100989U A SG11202100989U A SG 11202100989UA SG 11202100989U A SG11202100989U A SG 11202100989UA SG 11202100989U A SG11202100989U A SG 11202100989UA
Authority
SG
Singapore
Prior art keywords
fusion protein
protein specific
novel fusion
novel
specific
Prior art date
Application number
SG11202100989UA
Other languages
English (en)
Inventor
Marina Pavlidou
Lucia Pattarini
Alix Scholer-Dahirel
Christine Rothe
Shane Olwill
Aiba Rachida Bel
Marlon Hinner
Janet Peper
Original Assignee
Pieris Pharmaceuticals Gmbh
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pieris Pharmaceuticals Gmbh, Servier Lab filed Critical Pieris Pharmaceuticals Gmbh
Publication of SG11202100989UA publication Critical patent/SG11202100989UA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
SG11202100989UA 2018-07-31 2019-07-31 Novel fusion protein specific for cd137 and pd-l1 SG11202100989UA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18186445 2018-07-31
EP18204548 2018-11-06
PCT/EP2019/070596 WO2020025659A1 (en) 2018-07-31 2019-07-31 Novel fusion protein specific for cd137 and pd-l1

Publications (1)

Publication Number Publication Date
SG11202100989UA true SG11202100989UA (en) 2021-02-25

Family

ID=67480227

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202100989UA SG11202100989UA (en) 2018-07-31 2019-07-31 Novel fusion protein specific for cd137 and pd-l1

Country Status (28)

Country Link
US (1) US20210363257A1 (https=)
EP (2) EP3830120B9 (https=)
JP (1) JP7482488B2 (https=)
KR (1) KR20210040103A (https=)
CN (1) CN112789292A (https=)
AU (1) AU2019315703A1 (https=)
BR (1) BR112020025263A2 (https=)
CA (1) CA3100119A1 (https=)
CL (1) CL2021000207A1 (https=)
CY (1) CY1126148T1 (https=)
DK (1) DK3830120T5 (https=)
ES (1) ES2948717T3 (https=)
FI (1) FI3830120T3 (https=)
HR (1) HRP20230590T2 (https=)
HU (1) HUE062320T2 (https=)
IL (1) IL279541A (https=)
LT (1) LT3830120T (https=)
MD (1) MD3830120T3 (https=)
MX (1) MX2021000401A (https=)
MY (1) MY200710A (https=)
PH (1) PH12021550001A1 (https=)
PL (1) PL3830120T3 (https=)
RS (1) RS64343B9 (https=)
SG (1) SG11202100989UA (https=)
SI (1) SI3830120T1 (https=)
TW (1) TWI837156B (https=)
WO (1) WO2020025659A1 (https=)
ZA (1) ZA202100125B (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210096640A (ko) * 2018-11-29 2021-08-05 하버 바이오메드 테라푸틱스 리미티드 항-pd-l1 항체 제제
EP3946417A1 (en) * 2019-03-29 2022-02-09 Pieris Pharmaceuticals GmbH Inhaled administration of lipocalin muteins
JP7634001B2 (ja) 2019-10-11 2025-02-20 ナンチン リーズ バイオラブス カンパニー，リミティド ４－１ｂｂに結合する抗体およびその用途
EP4161957A1 (en) 2020-06-05 2023-04-12 Pieris Pharmaceuticals GmbH Multimeric immunomodulator targeting 4-1bb
CA3191224A1 (en) * 2020-10-16 2022-04-21 Shenda GU Multispecific binding compounds that bind to pd-l1
IL304295B2 (en) * 2021-01-08 2025-07-01 Beijing Hanmi Pharmaceutical Co Ltd Anti-pd-l1/anti-4-1bb natural antibody structure-like heterodimeric form bispecific antibody and preparation thereof
CN115521379B (zh) * 2021-07-16 2023-12-22 南京吉盛澳玛生物医药有限公司 Pd-1抗体及其用途
CN115677858A (zh) * 2021-07-23 2023-02-03 合肥瀚科迈博生物技术有限公司 一种能够靶向cd137和pd-l1的双特异性抗体的用途
CN114736303A (zh) * 2022-03-17 2022-07-12 英诺湖医药(杭州)有限公司 抗pd-l1和4-1bb的双功能抗体及其医药用途
WO2023180523A1 (en) 2022-03-24 2023-09-28 Pieris Pharmaceuticals Gmbh Process for purifying fusion proteins
JP2025532652A (ja) * 2022-09-21 2025-10-01 シージェン インコーポレイテッド Ｃｄ１３７およびｃｄ２２８に特異的な新規融合タンパク質
CN116211860B (zh) * 2023-05-10 2023-08-22 细胞生态海河实验室 Ck2抑制剂cx4945在制备肿瘤治疗中防止免疫细胞耗竭药物应用、抑制剂及联合物

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
JPH01215289A (ja) 1988-02-22 1989-08-29 Toa Nenryo Kogyo Kk 遺伝子組換えによる正常ヒト血清アルブミンａの製造方法
FR2649991B2 (fr) 1988-08-05 1994-03-04 Rhone Poulenc Sante Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
ATE207080T1 (de) 1991-11-25 2001-11-15 Enzon Inc Multivalente antigen-bindende proteine
US5728553A (en) 1992-09-23 1998-03-17 Delta Biotechnology Limited High purity albumin and method of producing
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US6080560A (en) 1994-07-25 2000-06-27 Monsanto Company Method for producing antibodies in plant cells
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
US6620413B1 (en) 1995-12-27 2003-09-16 Genentech, Inc. OB protein-polymer chimeras
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
CA2233725A1 (en) 1998-03-31 1999-09-30 Hemosol Inc. Hemoglobin-hydroxyethyl starch complexes
DK1087778T3 (da) 1998-06-08 2005-12-19 Hoffmann La Roche Anvendelse af PEG-IFN-alfa og Ribavirin til behandling af kronisk hepatitis C
US6403564B1 (en) 1998-10-16 2002-06-11 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
AU2002335930B2 (en) 2001-03-09 2005-07-28 Morphosys Ag Serum albumin binding moieties
WO2005019255A1 (en) 2003-08-25 2005-03-03 Pieris Proteolab Ag Muteins of tear lipocalin
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
US7892827B2 (en) 2004-11-26 2011-02-22 Pieris Ag Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4)
JP2009509535A (ja) 2005-09-27 2009-03-12 アムニクス， インコーポレイテッド タンパク様薬剤およびその使用
AU2015205530B8 (en) 2014-01-13 2019-09-19 Pieris Pharmaceuticals Gmbh Multi-specific polypeptide useful for localized tumor immunomodulation
JP6783797B2 (ja) * 2015-05-04 2020-11-11 ピエリス ファーマシューティカルズ ゲーエムベーハー 抗がん融合ポリペプチド
CN114573680A (zh) * 2015-05-04 2022-06-03 皮里斯制药有限公司 Cd137特异性的蛋白
EP3298030B1 (en) * 2015-05-18 2023-01-18 Pieris Pharmaceuticals GmbH Anti-cancer fusion polypeptide
KR20180096789A (ko) * 2016-01-11 2018-08-29 인히브릭스, 인크. 다가 및 다중특이적 41bb-결합 융합 단백질
RU2693661C2 (ru) * 2016-03-04 2019-07-03 Сычуань Келунь-Байотек Байофармасьютикал Ко., Лтд. Антитело против pdl-1, его фармацевтическая композиция и применение
UA126905C2 (uk) * 2016-06-13 2023-02-22 Ай-Маб Байофарма Юес Лімітед Антитіло до pd-l1 та його застосування
WO2018087108A1 (en) * 2016-11-09 2018-05-17 Pieris Pharmaceuticals Gmbh Proteins specific for cd137
CN107082812B (zh) * 2017-03-29 2018-11-13 上海科医联创生物科技有限公司 一种恢复衰竭性免疫细胞功能的融合蛋白及其应用
CN110799546B (zh) * 2017-09-01 2023-01-24 四川科伦博泰生物医药股份有限公司 重组双特异性抗体
WO2023000675A1 (zh) * 2021-07-23 2023-01-26 安徽安科生物工程（集团）股份有限公司 靶向pd-l1和4-1bb的双特异性抗体

Also Published As

Publication number Publication date
PL3830120T3 (pl) 2023-10-09
AU2019315703A1 (en) 2020-12-10
HUE062320T2 (hu) 2023-10-28
SI3830120T1 (sl) 2023-10-30
MX2021000401A (es) 2021-03-25
JP2021533203A (ja) 2021-12-02
BR112020025263A2 (pt) 2021-03-09
EP3830120B1 (en) 2023-05-24
CL2021000207A1 (es) 2021-08-13
IL279541A (en) 2021-01-31
KR20210040103A (ko) 2021-04-12
MD3830120T3 (ro) 2023-11-30
CY1126148T1 (el) 2023-11-15
US20210363257A1 (en) 2021-11-25
HRP20230590T1 (hr) 2023-09-15
RS64343B9 (sr) 2023-11-30
EP4249064A2 (en) 2023-09-27
FI3830120T3 (fi) 2023-06-13
JP7482488B2 (ja) 2024-05-14
EP3830120A1 (en) 2021-06-09
DK3830120T5 (da) 2024-08-19
ZA202100125B (en) 2023-06-28
MY200710A (en) 2024-01-12
PH12021550001A1 (en) 2021-09-27
WO2020025659A1 (en) 2020-02-06
CN112789292A (zh) 2021-05-11
CA3100119A1 (en) 2020-02-06
LT3830120T (lt) 2023-07-10
HRP20230590T2 (hr) 2024-02-16
ES2948717T3 (es) 2023-09-18
RS64343B1 (sr) 2023-08-31
DK3830120T3 (da) 2023-06-26
TW202019967A (zh) 2020-06-01
EP3830120B9 (en) 2023-08-30
MD3830120T2 (ro) 2023-08-31
EP4249064A3 (en) 2023-12-06
TWI837156B (zh) 2024-04-01

Similar Documents

Publication Publication Date Title
ZA202100125B (en) Novel fusion protein specific for cd137 and pd-l1
IL284687A (en) Novel fusion proteins specific for CD137 and GPC3
GB2564823B8 (en) Compositions and methods for TCR reprogramming using fusion proteins
EP3298033A4 (en) Compositions and methods for tcr reprogramming using fusion proteins
SG11202012004SA (en) Rna-targeting fusion protein compositions and methods for use
EP3287470A4 (en) Novel recombinant bi-functional fusion protein and preparation and application therefor
SG11202008721SA (en) Compositions and methods for tcr reprogramming using fusion proteins
EP3147298A4 (en) Pd-l1 fusion protein and use thereof
GB201509782D0 (en) Methods and products for fusion protein synthesis
SG11202101904UA (en) Spd-1 variant - fc fusion proteins
IL287318A (en) Materials and methods for the production of proteins
ZA202003845B (en) Fusion proteins
IL291236A (en) Compositions and methods for reprogramming tcr using fusion proteins
GB201800334D0 (en) Modified protein
SG11202101811VA (en) Compositions and methods for tcr reprogramming using fusion proteins
IL297395B1 (en) btla fusion protein agonists and uses thereof
SG11202000775SA (en) Fusion tags for recombinant protein expression
ZA202102533B (en) Fusion protein
IL281397B (en) Human pd–l1 antibodies
EP4034565A4 (en) CHIMERIC PROTEINS TARGETED AGAINST PD-L1 AND USES THEREOF
IL291284A (en) Systems and methods for expression of proteins
ZA202003722B (en) Modified globin proteins
GB201704006D0 (en) Modified globin proteins
PT3830120T (pt) Nova proteína de fusão específica para cd137 e pd-l1
GB201712792D0 (en) Fusion protein